Evgeny Bazdyrev

Dr. Evgeny Bazdyrev

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
EBEvgeny Bazdyrev
Evgeny Bazdyrev
PRPolina Rusina
Polina Rusina
MPMaria Panova
Maria Panova
Fedor NovikovFedor Novikov
Fedor Novikov
IGIvan Grishagin
Ivan Grishagin
VNVladimir Nebolsin
Vladimir Nebolsin
At the end of 2019, a highly contagious infection began its ominous conquest of the world. It was soon discovered that the disease was caused by a novel coronavirus designated as SARS-CoV-2, and the disease was thus abbreviated to COVID-19 (COVID). The global medical community has directed its efforts not only to find effective therapies against the deadly pathogen but also to combat the concomitant complications. Two of the most common respiratory manifestations of COVID are a significant reduction in the diffusing capacity of the lungs (DLCO) and the associated pulmonary interstitial damage. One year after moderate COVID, the incidence rate of impaired DLCO and persistent lung damage still exceeds 30%, and one-third of the patients have severe DLCO impairment and fibrotic lung damage. The persistent respiratory complications may cause substantial population morbidity, long-term disability, and even death due to the lung fibrosis progression. The incidence of COVID-induced pulmonary fibrosis caused by COVID can be estimated based on a 15-year observational study of lung pathology after SARS. Most SARS patients with fibrotic lung damage recovered within the first year and then remained healthy; however, in 20% of the cases, significant fibrosis progression was found in 5–10 years. Based on these data, the incidence rate of post-COVID lung fibrosis can be estimated at 2–6% after moderate illness. What is worse, there are reasons to believe that fibrosis may become one of the major long-term complications of COVID, even in asymptomatic individuals. Currently, despite the best efforts of the global medical community, there are no treatments for COVID-induced pulmonary fibrosis. In this review, we analyze the latest data from ongoing clinical trials aimed at treating post-COVID lung fibrosis and analyze the rationale for the current drug candidates. We discuss the use of antifibrotic therapy for idiopathic pulmonary fibrosis, the IN01 vaccine, glucocorticosteroids as well as the stromal vascular fraction for the treatment and rehabilitation of patients with COVID-associated pulmonary damage.

16 December 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
EBEvgeny Bazdyrev
Evgeny Bazdyrev
MPMaria Panova
Maria Panova
VZValeria Zherebtsova
Valeria Zherebtsova
ABAlexandra Burdenkova
Alexandra Burdenkova
IGIvan Grishagin
Ivan Grishagin
VNVladimir Nebolsin
Vladimir Nebolsin
Since the beginning of the COVID-19 pandemic, clinical, radiological, and histopathological studies have provided evidence that organizing pneumonia is a possible consequence of the SARS-CoV2 infection. This post-COVID-19 organizing pneumonia (PCOP) causes persisting dyspnea, impaired pulmonary function, and produces radiological abnormalities for at least 5 weeks after onset of symptoms. While most patients with PCOP recover within a year after acute COVID-19, 5–25% of cases need specialized treatment. However, despite substantial resources allocated worldwide to finding a solution to this problem, there are no approved treatments for PCOP. Oral corticosteroids produce a therapeutic response in a majority of such PCOP patients, but their application is limited by the anticipated high-relapse frequency and the risk of severe adverse effects. Herein, we conduct a systematic comparison of the epidemiology, pathogenesis, and clinical presentation of the organizing pneumonias caused by COVID-19 as well as other viral infections. We also use the clinical efficacy of corticosteroids in other postinfection OPs (PIOPs) to predict the therapeutic response in the treatment of PCOP. Finally, we discuss the potential application of a candidate anti-inflammatory and antifibrotic therapy for the treatment of PCOP based on the analysis of the latest clinical trials data.

24 June 2020 in Complex Issues of Cardiovascular Diseases
Verified
Journal Article
Open access
PDF file
EBEvgeny Bazdyrev
Evgeny Bazdyrev
A series of unexplained cases with pneumonia have been reported in China since December 2019. Subsequent studies have found a novel strain of coronavirus, SARS-CoV-2, as the causative agent of acute infectious disease that has been named as coronavirus disease 2019 (COVID-19). COVID-19 has outbroken as a global pandemic affecting over 200 countries. This review focuses on a novel coronovirus disease, reporting all available data on its etiology, epidemiology, pathogenesis, clinical manifestations, principles of diagnosis and treatment. In addition, the impact of COVID on the cardiovascular system is highlighted.

10 July 2017 in Patologiya krovoobrashcheniya i kardiokhirurgiya
Verified
Journal Article
Open access
PDF file
EBEvgeny Bazdyrev
Evgeny Bazdyrev
ОПО. М. Поликутина
О. М. Поликутина
НКН. А. Каличенко
Н. А. Каличенко
YSYu. Slepynina
Yu. Slepynina
ОБО. Л. Барбараш
О. Л. Барбараш
ЮСЮ. С. Слепынина
Ю. С. Слепынина
Aim. The study was designed to analyze the relationship between a baseline function of the respiratory system and the incidence of cardiorespiratory complications in patients with coronary artery disease following planned coronary artery bypass grafting under cardiopulmonary bypass.Methods. A prospective cohort of 662 coronary artery disease patients was studied after approval by the local ethics committee. The patients were divided into 3 groups depending on the presence of respiratory diseases and ventilation disorders. The 1st group included 48 (7.2%) patients with respiratory system pathology having no obstructive disorders. The 2nd group had 248 (37.5%) patients with pulmonary diseases and respiratory obstruction. The 3rd group comprised 366 (55.3%) patients without diseases and instrumental signs of ventilation disorders.Results. The largest amount of postoperative complications was observed in patients with bronchial obstruction. Thus, respiratory complications in this group accounted for 20.9% vs. 8.3% (р = 0.036) of patients with respiratory pathology but without ventilation disorders and 4.6% (р = 0.001) of patients with isolated coronary artery disease. The development of cardiac complications had no differences among the patients with pulmonary diseases (35.4% and 48.8%, р≥0.05) regardless of the presence of respiratory obstruction, but as compared to the patients without indications of respiratory system pathology, the number of complications prevailed in patients with bronchial obstruction (48.8% and 25.4%; р = 0.001). The patients of these groups differed in the incidence of such complications as development of lower respiratory tract infections [nosocomial pneumonia (5.2% and 2.3%, р = 0.024), acute bronchitis and/or recrudescence of chronic bronchitis 14.1% and 2.9%; р = 0.001)], pneumothorax (4.1% and 0.6%, р = 0.006), as well as in the duration of artificial pulmonary ventilation (1003.7 min vs. 781 and 747.6 min, with p equaling 0.003 to 0.004). These complications more often developed in patients with respiratory obstruction, the incidence of complications was the same among the patients with the burdened respiratory history without ventilation disorders and the patients with isolated coronary artery disease. A similar tendency was observed when comparing the incidence of cardiac complications development. Paroxysms or a persistent form of atrial fibrillations (29% and 15.8%; р = 0.001), as well as decompensation of heart failure (25.4% and 13.9%; р = 0.001) were the most frequent complications. Conclusion. The presence of respiratory obstruction is an unfavorable prognostic factor for postoperative cardiorespiratory complications.Received 15 November 2016. Accepted 14 February 2017.Funding: The study did not have sponsorship.Conflict of interest: The authors declare no conflict of interest.Author contributions Study concept and design: E.D. Bazdyrev, O.M. Polikutina, N.A. Kalichenko, Yu.S. Slepynina, O.L. Barbarash.Data collection and analysis: E.D. Bazdyrev, N.A. Kalichenko.Drafting the article: E.D. Bazdyrev, O.M. Polikutina, N.A. Kalichenko, Yu.S. Slepynina, O.L. Barbarash.Critical revision of the article: E.D. Bazdyrev, O.L. Barbarash.Final approval of the version to be published: E.D. Bazdyrev, O.M. Polikutina, N.A. Kalichenko, Yu.S. Slepynina, O.L. Barbarash.

3 November 2022 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
EBEvgeny Bazdyrev
Evgeny Bazdyrev
MPMaria Panova
Maria Panova
MBMaria Brachs
Maria Brachs
ESElena Smolyarchuk
Elena Smolyarchuk
DTDaria Tsygankova
Daria Tsygankova
Fedor NovikovFedor Novikov
Fedor Novikov
Background: Many patients who recovered from COVID are still suffering from pulmonary dysfunction that can be persistent even for months after infection. Therefore, treatment to prevent irreversible impairment of lung function is needed. Treamid (bisamide derivative of dicarboxylic acid, BDDA) was shown to have anti-inflammatory and antifibrotic effects in animal models of pulmonary fibrosis. This study was designed to assess the safety, tolerability, and efficacy of Treamid in the rehabilitation of patients after COVID pneumonia. The aim was to establish whether Treamid could be effective in ameliorating post-COVID sequelae. Methods: The phase 2, randomized, double-blind, placebo-controlled clinical trial was done at 8 medical centers in Russia. Patients with a diagnosis of COVID in the past medical history (with the first symptoms of COVID appear no earlier than 2 months before screening) and having fibrotic changes in the lungs, decreased lung function (percentage of predicted FVC and/or DLCO < 80%), and moderate or severe dyspnea according to mMRC scale were enrolled and randomly assigned in a 1:1 ratio (stratified by the initial degree of lung damage, age, and concomitant chronic diseases) by use of interactive responsive technology to peroral administration of Treamid 50 mg or placebo once a day for 4 weeks. The primary outcome was the proportion of patients who achieved clinically significant improvement in FVC and/or DLCO (defined as a relative increase in FVC of ≥ 10% or a relative increase in FVC in the range of ≥ 5 to < 10% plus a relative increase in DLCO of ≥ 15%) at week 4 compared with baseline. Secondary endpoints included changes from baseline in dyspnea scoring evaluated by the modified Borg and mMRC scales, pulmonary function (FEV1, FVC, FEV1/FVC ratio, DLCO, TLC, FRC), 6-min walk distance, the overall score of the KBILD questionnaire, and the proportion of patients with a reduction in the degree of lung damage assessed by CT scores. This trial was registered on ClinicalTrials.gov (Identifier: NCT04527354). The study was fully funded by PHARMENTERPRISES LLC. Results: 12 out of 29 patients (41%) in Treamid group achieved clinically significant improvement in FVC and/or DLCO compared to 5 out of 30 patients (17%) in placebo group (p = 0.036). There was a significant decrease of dyspnea according to modified Borg scale observed in the Treamid group (− 0.9 ± 0.7 vs. − 0.4 ± 0.8, p = 0.018). No significant differences in the adverse events were noted. Exploratory analysis of the female population indicated superiority of Treamid over placebo by decreasing dyspnea and the extent of lung damage as well as increasing TLC. Conclusions: 4 weeks oral administration of 50 mg Treamid was associated with clinically significant improvement in the post-COVID patients, evident by an increase in FVC and/or DLCO as well as decreasing dyspnea. Treamid was well tolerated and can be safely administered to patients discharged after COVID. Treamid was more effective in women visible by superior improvement of COVID sequalae after 4 weeks treatment. Considering that female gender is a risk factor associated with the development of post-COVID symptoms, Treamid might offer a pharmacological treatment for long-term sequalae after COVID and supports further investigation in future clinical trials in post-COVID patients.

13 July 2021 in Rational Pharmacotherapy in Cardiology
Verified
Journal Article
Open access
PDF file
EBEvgeny Bazdyrev
Evgeny Bazdyrev
NTN. A. Terentyeva
N. A. Terentyeva
KKKristina Krivoshapova
Kristina Krivoshapova
VMV. L. Masenko
V. L. Masenko
EWE. A. Wegner
E. A. Wegner
OBOlga Barbarash
Olga Barbarash
Aim. To study the prevalence of musculoskeletal disorders in patients with stable coronary artery disease (CAD).Material and methods. Patients with stable CAD (n=387) were included in the study. The subjects were admitted to the hospital for planned myocardial revascularization (ages of 50-82). The median age was 65 [59;69] years. Most of the sample consisted of males - 283 (73.1%). 323 (83.5%) patients had arterial hypertension (AH), 57.1% - history of myocardial infarction, and a quarter of the patients had type 2 diabetes mellitus (DM). The study of musculoskeletal system included the identification of sarcopenia in accordance with The European Working Group on Sarcopenia in Older People (EWGSOP, 2019); verification of osteopenia/osteoporosis according to the WHO criteria (2008); diagnosing osteosarcopenia in case of sarcopenia and osteopenia/osteoporosis coexistence.Results. At the initial screening of sarcopenia in accordance with EWGSOP, clinical signs (according to the Strength, assistance with walking, rising from a chair, climbing stairs, and falls (SARC-F) questionnaire) were detected in 41.3% of cases, but further examination (dynamometry, quantitative assessment of skeletal muscle) confirmed this diagnosis only in 19.9% of patients with CAD. Among the examined patients with CAD a low T-score according to DEXA was found in 53 (13.7%) of cases, and osteopenia was diagnosed 10 times more often than osteoporosis (90.6% vs. 9.4%). Furthermore, due to combination of low bone density (osteopenia/osteoporosis) and reduced muscle mass and strength (sarcopenia), osteosarcopenia was verified in one patient. Thus, the study revealed the prevalence of particular types of musculoskeletal disorders in 105 (27.1%) patients with stable CAD. The most common type of musculoskeletal disorder was sarcopenia - 52 cases (13.4%); osteopenia/osteoporosis was detected in 28 patients (7.2%), osteosarcopenia in 25 (6.5%). The most pronounced clinical manifestation of sarcopenia and osteopenia/osteoporosis, reflected by a higher score on the SARC-F questionnaire, low handgrip strength, small area of muscle tissue, low musculoskeletal index, as well as low values of bone mineral density, were observed in patients with osteosarcopenia. Patients with osteopenia/osteoporosis did not differ significantly from patients without musculoskeletal conditions in most parameters, with the exception of the T-score, the average SARC-F score, and muscle strength in men. The conducted correlation analysis revealed not only the relationship between the parameters of musculoskeletal function, but also their association with age, duration of AH, CAD, and type 2 DM.Conclusion. Several types of musculoskeletal disorders were found in a third of patients with CAD. Sarcopenia was revealed to be the most frequent type of musculoskeletal disorder.